...
首页> 外文期刊>Neuropathology and applied neurobiology >Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.
【24h】

Molecular analysis of the EGFR gene in astrocytic gliomas: mRNA expression, quantitative-PCR analysis of non-homogeneous gene amplification and DNA sequence alterations.

机译:星形细胞胶质瘤中EGFR基因的分子分析:mRNA表达,非均质基因扩增和DNA序列改变的定量PCR分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with tyrosine kinase activity. This report investigates the presence of mutations, amplification and/or over-expression of the EGFR gene in 86 glial tumours including 44 glioblastomas, 21 anaplastic astrocytomas, and 21 WHO grade II astrocytomas, using polymerase chain reaction/single-strand conformation polymorphism, semiquantitative reverse-transcription-polymerase chain reaction (RT-PCR) and Southern Blot techniques. Gene amplification values were found in 34 tumours. Amplification levels were not uniform, as the transmembrane region presented lower amplification rates than extra- and intracellular domains. For the 19 samples with sufficient available tumour tissue we found over-expression in 11, and no EGFR mRNA expression in three. Ten cases showed deletion transcripts, and EGFR VIII was identified in all of these cases. One of the cases with EGFR vIII also presented a truncated form, C-958, while another showed an in frame tandem duplication of exons 18--25. We found 14 cases with sequence/structure gene alterations, including seven on which genomic novel DNA changes were identified: a missense mutation (1052C > T/Ala265Val), an insertion (InsCCC2498/Ins Pro748), three intronic changes (E6+72delG, E22--14C>G and E18--109T>C), a new polymorphic variant E12+ 22A > T, and one case that presented a 190 bp insertion, that was produced by the intron-7-exon-8 duplication and generated a truncated EGFR with intact exons 1--8 followed by an additional amino acidic sequence: Val-Ile-Met-Trp. These findings corroborate that EGFR is non-randomly involved in malignant glioma development and that different mutant forms participate in aberrant activation of tyrosine kinase pathways.
机译:表皮生长因子受体(EGFR)是一种具有酪氨酸激酶活性的跨膜糖蛋白。本报告使用聚合酶链反应/单链构象多态性,半定量研究调查了86个神经胶质瘤中EGFR基因的突变,扩增和/或过表达,其中包括44个胶质母细胞瘤,21个间变性星形细胞瘤和21个WHO II级星形细胞瘤。逆转录聚合酶链反应(RT-PCR)和Southern Blot技术。在34个肿瘤中发现了基因扩增值。扩增水平不均匀,因为跨膜区域呈现出比细胞外和细胞内域更低的扩增速率。对于具有足够可用肿瘤组织的19个样品,我们发现11个细胞中有过表达,而三个蛋白中没有EGFR mRNA表达。 10例表现出缺失转录本,在所有这些病例中均鉴定出EGFR VIII。 EGFR vIII的一例也呈截短形式C-958,而另一例表现出18--25外显子的框内串联重复。我们发现了14例序列/结构基因发生改变的病例,其中有7例发现了基因组新的DNA改变:错义突变(1052C> T / Ala265Val),插入(InsCCC2498 / Ins Pro748),三个内含子改变(E6 + 72delG, (E22--14C> G和E18--109T> C),一种新的多态性变体E12 + 22A> T,一种情况是插入190 bp,由内含子7-外显子8重复产生并产生了带有完整外显子1--8的截短EGFR,其后还有一个氨基酸序列:Val-Ile-Met-Trp。这些发现证实了EGFR是非随机地参与恶性神经胶质瘤的发展,并且不同的突变体形式参与了酪氨酸激酶途径的异常激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号